Not FDA approvedRegenerative / research
TB-500
A research-market recovery compound with no established consumer indication and a substantial human-data gap.
ReceptorunknownRoutessubcutaneous, intramuscularConfidencelow
Visible for broad education until a goal is selected.
Not FDA approved; no consumer protocol is provided.
Useful for
- Understanding the evidence gap behind named recovery stacks
- Preparing questions when a clinic offers TB-500
Not established for
- An executable recovery protocol
- Self-injection
- Human dosing
Evidence receipts
Limited dataReviewed 2026-07-12
Consumer recovery useFDA reports no identified human exposure data for compounded TB-500 and notes potential immunogenicity and peptide-impurity risks.
This is not an FDA-approved therapy and the platform does not provide a protocol or sourcing path.